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ABSTRACT
Objectives To investigate potential determinants of
severe hypoglycaemia, including baseline
characteristics, in the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) trial and the association of
severe hypoglycaemia with levels of glycated
haemoglobin(haemoglobinA1C)achievedduringtherapy.
DesignPosthocepidemiologicalanalysisofadouble2×2
factorial, randomised, controlled trial.
Setting Diabetes clinics, research clinics, and primary
care clinics.
Participants10209ofthe10251participantsenrolledin
the ACCORD study with type 2 diabetes, a haemoglobin
A1C concentration of 7.5% or more during screening, and
aged 40-79 years with established cardiovascular
disease or 55-79 years with evidence of significant
atherosclerosis, albuminuria, left ventricular
hypertrophy, or two or more additional risk factors for
cardiovascular disease (dyslipidaemia, hypertension,
current smoker, or obese).
Interventions Intensive (haemoglobin A1C <6.0%) or
standard (haemoglobin A1C 7.0-7.9%) glucose control.
Main outcome measures Severe hypoglycaemia was
defined as episodes of “low blood glucose” requiring the
assistance of another person and documentation of
either a plasma glucose less than 2.8 mmol/l (<50 mg/dl)
or symptoms that promptly resolved with oral
carbohydrate, intravenous glucose, or glucagon.
Results The annual incidence of hypoglycaemia was
3.14% in the intensive treatment group and 1.03% in the
standard glycaemia group. We found significantly
increased risks for hypoglycaemia among women
(P=0.0300), African-Americans (P<0.0001 compared with
non-Hispanic whites), those with less than a high school
education (P<0.0500 compared with college graduates),
aged participants (P<0.0001 per 1 year increase), and
those who used insulin at trial entry (P<0.0001). For every
1% unit decline in the haemoglobin A1C concentration
from baseline to 4 month visit, there was a 28% (95% CI
19% to 37%) and 14% (4% to 23%) reduced risk of
hypoglycaemia requiring medical assistance in the
standard and intensive groups, respectively. In both
treatment groups, the risk of hypoglycaemia requiring
medical assistance increased with each 1% unit
increment in the average updated haemoglobin A1C
concentration (standard arm: hazard ratio 1.76, 95% CI
1.50 to 2.06; intensive arm: hazard ratio 1.15, 95% CI
1.02 to 1.21).
Conclusions A greater drop in haemoglobin A1C
concentration from baseline to the 4 month visit was not
associated with an increased risk for hypoglycaemia.
Patients with poorer glycaemic control had a greater risk
of hypoglycaemia, irrespective of treatment group.
Identification of baseline subgroups with increased risk
for severe hypoglycaemia can provide guidance to
clinicians attempting to modify patient therapy on the
basis of individual risk.
TrialregistrationClinicalTrials.govnumberNCT00000620.
INTRODUCTION
Hypoglycaemiaisthemostimportantadverseeffectof
intensive glycaemic management in patients with dia-
betes. Severe episodes can be accompanied by confu-
sion,disorientation,irrationalbehaviour,convulsions,
coma, permanent impairment of brain function, ser-
ious injury, and even death. Hypoglycaemia is
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BMJ | ONLINE FIRST | bmj.com page 1 of 12particularly dangerous if it occurs while patients are
drivingoroperatingpotentiallyhazardousmachinery,
and in those living alone with no one to provide assis-
tance. Asymptomatic episodes may be accompanied
by silent myocardial ischaemia.
1 Loss of warning
signs (hypoglycaemia unawareness) and severe epi-
sodes become more prevalent as glycaemia control
improves to the point that glucose levels are at normal
or near normal levels. Indeed, hypoglycaemia has
been identified as the limiting factor that prevents
patientswithdiabetesfromachievingexcellentglycae-
mic control.
23
The Diabetes Control and Complications Trial
(DCCT) reported 62 episodes of severe hypoglycae-
mia requiring assistance for treatment per 100 person
years in patients with type 1 diabetes treated inten-
sively to a target of normoglycaemia,
4 which was
three times higher than the event rate in patients on
standard treatment. Although the incidence of severe
hypoglycaemia is typically lower in patients with type
2 diabetes than in those with type 1 diabetes, it is not
inconsequential. Estimates of the incidence of severe
hypoglycaemia in patients with type 2 diabetes vary,
depending on definitions and methods of ascertain-
ment.Theincidenceofseverehypoglycaemiaininten-
sively treated patients in clinical trials ranges from as
low as 0.7 events per 100 person years in the Action in
Diabetes and Vascular Disease: Preterax and Diami-
cron Modified Release Controlled Evaluation
(ADVANCE) study
5 and 1.8 patients per 100 person
years with insulin treatment in the UK Prospective
Diabetes Study (UKPDS),
6 to nine episodes with
impaired consciousness per 100 person years in the
Veterans Affairs Diabetes Trial (VADT).
7 In epide-
miological studies, higher frequencies of 12,
8 15,
9
28,
10 and 35
11 episodes per 100 person years have
beenreported.Mostsevereepisodesoccurwithinsulin
or sulphonylurea treatment.
12
The Action to Control Cardiovascular Risk in Dia-
betes(ACCORD)trialwasdesignedtotestthehypoth-
esisthatreducingbloodglucoseconcentrationstonear
normallevelsinadultswithtype2diabetesathighrisk
ofacardiovasculareventwouldresultinareductionin
non-fatal and fatal cardiovascular disease. The
ACCORD glycaemia trial compared intensive treat-
ment aimed at achieving normoglycaemia (target gly-
cated haemoglobin (haemoglobin A1C) concentration
<6.0%) with standard treatment (target haemoglobin
A1C level 7.0-7.9%) in individuals with type 2 diabetes
agedeither40-79yearswithestablishedcardiovascular
disease or 55-79 years with evidence of significant
atherosclerosis,albuminuria,leftventricularhypertro-
phy, or two or more additional risk factors for cardio-
vascular disease. The primary outcome of the
ACCORD study was a composite of non-fatal myo-
cardial infarction, non-fatal stroke, or death from
cardiovascular causes.
The median haemoglobin A1C concentration in the
intensive treatment group after randomisation was
6.4%,
13 and reached as low as 6.0% at certain times in
some ACCORD clinics. In February 2008, the
intensive glycaemia control intervention was stopped
early because of higher mortality in this study arm:
1.42 deaths per 100 person years compared with 1.14
deaths per 100 person years in the standard treatment
arm (hazard ratio (HR) 1.22, 95% confidence interval
(CI) 1.01 to 1.46; P=0.04).
13 The intensive treatment
group also exhibited significantly higher cardio-
vascular disease related mortality and did not have a
significantly lower incidence of major cardiovascular
events compared with patients in the standard treat-
ment arm.
Special attention was given to monitoring and mini-
mising severe hypoglycaemia in the ACCORD study
because of concern regarding the consequences of
hypoglycaemia in this older population.
14 No link has
been found between the increased mortality observed
in the intensive glycaemia control group and severe
hypoglycaemia.
15
A severe hypoglycaemic episode is an important
clinical event that causes both physician anxiety and
patient distress and that occurs in patients treated
both intensively and more conservatively. Identifica-
tion of risk factors for severe hypoglycaemia can help
to guide therapy decisions and ultimately may reduce
theriskofsuchanevent.Thispaperdescribesboththe
baseline determinants of severe hypoglycaemia and
the relation between the post-randomisation change
in haemoglobinA1C levels and the incidence of severe
hypoglycaemia in both treatment groups in the
ACCORD trial.
METHODS
Study design
The ACCORD study is a double 2×2 factorial, rando-
mised, controlled trial designed to test the effect of
intensiveglucosecontrolcomparedwithstandardcon-
troloncardiovascularoutcomesinpatientswithtype2
diabetes, and either intensive blood pressure control
versus standard control or a lipid strategy that targets
low density lipoprotein cholesterol, high density lipo-
protein, and triglyceride levels versus a strategy that
targets low density lipoprotein cholesterol levels
only.
1617 The full ACCORD study protocol is avail-
able at: http://www.accordtrial.org/web/public/docu
ments/Protocol%20All%20Chapters.pdf?
CFID=360349&CFTOKEN=40333908.
Study participants
Participants were eligible to enrol in the ACCORD
study if they had type 2 diabetes, a haemoglobin A1C
concentration of 7.5-11%, and were: a) between the
ages of 40 and 79 years with cardiovascular disease;
orb)betweentheagesof55and79yearswithevidence
of significant atherosclerosis, albuminuria, left ventri-
cular hypertrophy, or two or more additional risk fac-
tors for cardiovascular disease (dyslipidaemia,
hypertension,currentsmoking,orobesity).Keyexclu-
sions included a history of frequent or recent serious
hypoglycaemic events (hypoglycaemic coma or sei-
zure within the past 12 months or hypoglycaemia
RESEARCH
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months with concomitant glucose concentration of
less than 3.3 mmol/l (60 mg/dl)), unwillingness to do
home glucose monitoring, a body mass index of more
than45,aserumcreatinineconcentrationofmorethan
133 µmol/l (1.5 mg/dl)), or other serious illness.
A detailed description of the glycaemia treatment
algorithms used in the ACCORD study has been pre-
viously published.
17 Briefly, participants were ran-
domly assigned to receive intensive therapy targeting
a haemoglobin A1C concentration of less than 6.0% or
to receive standard therapy targeting a haemoglobin
A1C level of 7.0-7.9%. All participants were provided
withglucoseloweringmedicationsfromastudysuper-
vised formulary and glucose monitoring supplies,
including glucose meters with software that allowed
download of test results at clinic visits. Any marketed
glucose lowering medication not in the study formu-
lary could also be prescribed but was not provided by
the study.
Treatment regimens were individualised on the
basis of study group assignment and response to ther-
apy. Glucose medications were adjusted every two
months for participants in the intensive treatment
armandeveryfourmonthsforparticipantsinthestan-
dard arm, as needed to reach study goals. Medication
adjustments were based on a point of care haemoglo-
bin A1C measurement and data from participants’
home blood glucose meters or personal logs. Partici-
pants in the intensive arm were asked to self monitor
glucose at least two to four times a day if not on insulin
and four to eight times a day if on insulin. Haemoglo-
bin A1C concentration and other measurements used
in this report were obtained from blood samples col-
lectedatfourmonthclinicvisits.Allsampleswerecen-
trally analysed at the ACCORD central laboratory.
Atotalof10251participantswererandomisedinthe
ACCORD study: 1174 participants during a 20 week
vanguard period from January 2001 to June 2001 and
9077 in the main recruiting period between February
2003 and October 2005. The purpose of the vanguard
phase was to assess the feasibility of recruitment, the
likelihood of achieving glycaemia and blood pressure
treatment goals, and the probability of achieving an
acceptable level of adherence in the masked lipid
trial.Thisreportincludesdatasubmittedtothecoordi-
nating centre up until 10 December 2007, which were
used by the data and safety monitoring board to make
its recommendation to discontinue the intensive gly-
caemia intervention. The CONSORT diagram for
the ACCORD study can be found at: http://content.
nejm.org/cgi/data/NEJMoa0802743/DC1/1.
Definition of severe hypoglycaemia
At each visit, participants were asked about the occur-
rence, therapy, and consequences of hypoglycaemia,
andwhetheranyepisodesrequiredthemtoseekemer-
gency medical care or be admitted to hospital (defined
as hypoglycaemia requiring medical assistance
(HMA)). Participants were also asked if they had an
episode of “low blood glucose” requiring any assis-
tance, either medical or non-medical (hypoglycaemia
needingany assistance(HA)).AfterMarch2003,addi-
tional documentation of either a plasma glucose level
of less than 2.8 mmol/l (50 mg/dl) or symptoms that
promptly resolved with oral carbohydrate, intra-
venousglucose,orsubcutaneousorintramuscularglu-
cagon was also required for a diagnosis of severe
hypoglycaemia. Eighty five per cent of reported cases
of HA have such documentation.
Each case of HMA underwent additional review by
ACCORD investigators (fully described elsewhere).
14
Briefly,questionsaboutcircumstancessurroundingthe
event were asked, answers were reviewed by a local
ACCORD expert in diabetes treatment, and recom-
mendations were made to prevent future episodes.
Table 1 |Comparison of hypoglycaemia frequency per 100 person years
Type of hypoglycaemic episode
Standard glycaemia control Intensive glycaemia control
P value for incidence
comparison†
Frequency
(n (%))
Events* per 100
person years
Frequency
(n (%))
Events* per 100
person years
Episodes requiring medical assistance only (HMA; n= =717 participants)
No hypoglycaemic events 4913 (96.5)
Incidence=1.03
Overall=1.37
4579 (89.5)
Incidence=3.14
Overall=4.28
<0.0001
One hypoglycaemic event 134 (2.6) 403 (7.9)
Two hypoglycaemic events 35 (0.7) 85 (1.7)
Three or more hypoglycaemic events 10 (0.2) 50 (1.0)
Total with 1+ event 179 (3.5) 538 (10.6)
Episodes requiring either medical or non-medical assistance (HA; n= =1091 participants)
No hypoglycaemic events 4831 (94.9)
Incidence=1.51
Overall=2.31
4287 (83.8)
Incidence=5.05
Overall=8.25
<0.0001
One hypoglycaemic event 179 (3.5) 535 (10.5)
Two hypoglycaemic events 51 (1.0) 150 (2.9)
Three or more hypoglycaemic events 31 (0.6) 145 (2.8)
Total with 1+ event 261 (5.1) 830 (16.2)
*Incidence calculated as number of initial events divided by total person years of follow-up until initial event or censoring, multiplied by 100. Overall
events per 100 person years of follow-up calculated as total number of events divided by total person years of follow-up until censoring, multiplied
by 100. Numbers of events and participants followed differ slightly from those reported in our analysis relating hypoglycaemic events to mortality
15
because those analyses only included events occurring before regular visits that ascertained vital status.
†Obtained from log rank test.
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additional review by an outside expert was done and
haemoglobin A1C targets were relaxed according to
protocol(afterthethirdepisode).
14Thisreportincludes
allhypoglycaemiceventsreportedupuntilthetimethe
intensive glycaemia intervention was stopped.
13
Statistical analysis
Calculation of hypoglycaemia risk
Statistical analyses were conducted using SAS soft-
ware, version 9.1 (SAS Institute Inc, Cary, NC,
USA). The number and proportion of participants
with recurrent hypoglycaemic eventswas summarised
by glycaemiatreatmentgroup. Unadjustedannualised
incidenceofhypoglycaemiawascalculatedwithin gly-
caemia treatment groups by dividing the number of
individuals with events by the cumulative time
betweenrandomisationandtheinitialeventorcensor-
ing date. In addition, the total number of events per
100 person years of follow-up was calculated by divid-
ing the total number of events by the total number of
person years of follow-up. Distribution of the time to
first HMA event was compared between treatment
groups using Kaplan-Meier curves and log rank tests.
Adjusted annual rates of HMA were estimated using
Poisson regression models adjusted for age, gender,
education, and time since diagnosis of diabetes.
Comparison of HMA risk among baseline subgroups
Hazard ratios for the risk of HMA in the intensive arm
compared with the standard arm were calculated in
baselineparticipantsubgroupsusingCoxproportional
hazards regression models containing the baseline
variable, the glycaemia intervention effect, and the
interaction between the two variables. These models
also controlled for age, gender, education, and time
since diabetes diagnosis, as well as factors used to stra-
tifyrandomisation(thatis,treatmentgroupswithinthe
bloodpressureandlipidtrialsandthepresenceofclin-
ical cardiovascular disease). The baseline characteris-
tics were chosen a priori by the investigators on
the basis of factors anticipated to be related to hypo-
glycaemic risk (or possibly mortality).
15 Cut-off points
for continuous variables were also selected a priori.
Development of a predictive model for HMA using baseline
characteristics
A more fully adjusted model predictive of the time
until initial HMA event was also developed using pro-
portional hazards regression models. Candidate base-
line covariates were age, gender, living arrangement
(alone or with others), race, education, alcohol use,
body mass index, time since diagnosis of diabetes, his-
tory of cardiovascular disease, previous amputation of
an appendage, history of neuropathy or nerve
problems, baseline haemoglobin A1C concentration,
albumin to creatinine ratio, serum creatinine concen-
tration, systolic blood pressure, low density lipo-
protein cholesterol, use of beta blockers, and use of
the following glycaemia medications on entry to the
ACCORD trial (pre-randomisation): metformin; sul-
phonylureas; thiazolidinediones; and any insulin. For-
ward stepwise variable selection was used to construct
a single model based on a P value of less than 0.05 for
the covariates’ association with HMA. Interactions
between the glycaemia intervention and each covari-
ate identified as important in the above subgroup ana-
lyseswerealsoscreenedforinclusioninthefinalmodel
(labelled the comprehensive baseline model).
Post-randomisation levels of glucose control and the risk
of HMA
The effect of follow-up glucose control on the risk of
severehypoglycaemiawasanalysedusingfourdifferent
time varying variables to represent glucose control: a)
the updated average haemoglobin A1C during follow-
up (including the baseline measurement); b)t h em o s t
recenthaemoglobinA1C value; c)thechangeinhaemo-
globin A1C from baseline tothe updated average (base-
linevalueexcludedfromtheaverage);andd)thechange
in haemoglobin A1C from baseline to the four month
value.Giventhatthevaluesofathroughcchangeddur-
ing follow-up, these variables were recalculated for a
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Fig 1 |Plot of Kaplan-Meier estimates of the proportion of
participants with at least one episode of hypoglycaemia
requiring medical assistance
Follow-up (year)
P
r
o
p
o
r
t
i
o
n
 
w
i
t
h
 
e
v
e
n
t
s
r
e
q
u
i
r
i
n
g
 
m
e
d
i
c
a
l
 
a
s
s
i
s
t
a
n
c
e
 
(
%
)
123456
5092 Standard
arm
Number at risk
4913 4660 3163 1651 487
5117 Intensive
arm
4812 4519 2998 1621 441
0
2
3
4
1
Intensive glycaemia control
Standard glycaemia control
Fig 2 | Annual incidence of hypoglycaemia requiring medical
assistance by glycaemia treatment group and follow-up year.
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measurement was available. The updated values were
used to predict the risk of severe hypoglycaemia until a
new haemoglobin A1C measurement was obtained, at
which time the variable was updated again for the sub-
sequent follow-up interval.
Plots of the annual incidence of HMA against hae-
moglobin A1C concentration were created by dividing
eachhaemoglobinA1Cvariableintoquintilesandplot-
ting the annual incidence against the median haemo-
globin A1C value within the quintile. Proportional
hazards regression with time varying glucose control
covariates was used to calculate hazard ratios of the
risk of HMA by haemoglobin A1C level after adjust-
ment for variables in the comprehensive baseline
model. Initially, both linear and quadratic effects
were fitted for each haemoglobin A1C variable. Subse-
quently, interactions between each variable and gly-
caemia intervention were investigated. Final models
relating haemoglobin A1C variables to risk of HMA
retained haemoglobin A1C quadratic effects and inter-
actions that were statistically significant at P<0.05.
RESULTS
Overall risk of hypoglycaemia
FrequencycountsofincidentHMAandHAareshown
intable 1.Of the 10209 participantsin theACCORD
study with any follow-up for severe hypoglycaemia,
717 (7.0%) reported one or more episodes of HMA:
538 individuals in the intensive arm and 179 in the
standard arm. In addition, 374 (3.7%) participants
never reported an HMA event but reported one or
more episodes of severe hypoglycaemia that required
only non-medical assistance for treatment.
As expected, rates of both HA and HMA were
higher among participants assigned to intensive gly-
caemia therapy than in those on standard therapy.
Among participants in the intensive treatment group
(n=5117), 403 (7.9%) experienced one HMA event,
85 (1.7%) experienced two events, and 50 (1.0%)
experienced three or more events. In the standard
treatment group (n=5092), 134 (2.6%), 35 (0.7%), and
10 (0.2%) reported one, two, or three or more events,
respectively.
The incidence of initial HMA episodes per 100 per-
son years at risk was 3.14 among participants in the
intensive arm compared with 1.03 in those in the stan-
dard arm (log rank P<0.0001). Similarly, rates of HA
were higher among participants in the intensive arm
than among those in the standard arm (5.05 v 1.51; log
rankP<0.0001).Whenmultipleeventsinthesamepar-
ticipantwereconsidered,theoverallratesofHMAwere
4.28 per 100 person years at risk in the intensive arm
compared with 1.37 per 100 person years at risk in the
standard arm. The rates for HA were 8.25 and 2.31 per
100 person years at risk in the intensive and standard
groups, respectively (see table 1). Kaplan-Meier plots
of time to first HMA event by treatment group assign-
ment are shown in fig 1.
Estimates of annual incidence of HMA were calcu-
lated for each follow-up year by subtracting the pro-
duct limit estimates in the Kaplan-Meier plots from
one year to the next (fig 2). The incidence of HMA
according to this technique was consistently around
1% a year in the standard glycaemia control group.
Rates were highest amongparticipants in the intensive
arm during the first year of follow-up (3.4%), although
the incidence in this group steadily declined in each
subsequent year. Only participants recruited during
the vanguard phase are represented in year six of
follow-up because only vanguard participants were
followed for this long. When stratified by recruitment
time (vanguard v main trial; data not shown), partici-
pants in the intensive arm recruited during the van-
guard phase had similar rates of HMA to participants
in the intensive arm of the main trial in most years
except the initial year, where the rate of HMA in van-
guard participants was 5.62% and in main trial partici-
pants was 3.12%.
Hypoglycaemia risk according to baseline subgroups
The annual incidence of HMA in various subgroups
wasestimatedusingPoissonregressionafteradjustment
Overall
Age (years)
  <65
  65-69
  70-74
   ≥75
Gender
  Male
  Female
Living arrangements
  Living with others
  Living alone
Race
  Non-Hispanic white
  African-American
  Hispanic
  Other
Education
  Less than high school
  High school graduate
  Some college
  College graduate or more
Alcohol drinks per week
  None
  1-6
  ≥7
0.9005
0.0965
0.4421
0.4546
0.0477
0.6622
012345 78 6
Subgroup
Higher in
standard
therapy arm
Higher in
intensive
therapy arm
Intensive to standard
hazard ratio
Interaction
P value
2.80 (5117)
2.38 (3391)
3.04 (937)
4.25 (514)
5.27 (275)
2.62 (3136)
3.01 (1981)
2.70 (4087)
3.01 (1029)
2.69 (3208)
3.82 (993)
2.49 (358)
1.61 (558)
3.82 (803)
3.03 (1335)
2.55 (1670)
2.37 (1305)
2.71 (3908)
2.89 (975)
3.08 (232)
Intensive
glycaemia
control
0.90 (5092)
0.80 (3361)
1.00 (940)
1.39 (535)
1.39 (256)
0.86 (3139)
0.97 (1953)
0.84 (4052)
1.11 (1039)
0.79 (3215)
1.55 (946)
0.72 (374)
0.56 (557)
1.08 (708)
1.29 (1357)
0.87 (1675)
0.49 (1349)
0.91 (3857)
0.79 (994)
1.13 (238)
Standard
glycaemia
control
Annual incidence (%(N))
Fig 3 |Risk of hypoglycaemia requiring medical assistance by baseline demographic
subgroups. The dashed vertical line represents the overall intensive treatment to standard
treatment hazard ratio
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diabetes (figs 3, 4, and 5). Comparison of HMA risk in
the intensive treatmentarm and the standard treatment
arm identified several baseline subgroups that signifi-
cantlydifferedintheirintensivecontrolversusstandard
control hazard ratios (P for interaction<0.05). Within
thesesubgroups,thelargestintensivetostandardhazard
ratioswerefoundamongparticipantswiththefollowing
characteristics: a) college graduate (HR 4.90, 95% CI
3.17 to 7.55); b) diagnosed with diabetes 5 years ago or
less (HR 5.04, 95% CI 3.16 to 8.06); c)b a s e l i n e
haemoglobin A1C concentration of less than 7.5% (HR
7.24,95%CI4.14to12.67);d)systolicbloodpressureof
lessthan135mmHg(HR3.88,95%CI2.94to5.12);e)
lowdensitylipoproteincholesterollevelof2.59mmol/l
(100 mg/dl) or more (HR 4.03, 95% CI 3.12 to 5.20); f)
metformin use at baseline (HR 3.79, 95% CI 2.95 to
4.86); g) baseline use of sulphonylureas (HR 4.02, 95%
CI3.00to5.37);andh)absenceofinsulinuseatbaseline
(HR 5.42, 95% CI 3.94 to 7.44).
Baseline predictors of hypoglycaemia
Analysis of the variables in figs 3-5 by using forward
stepwise proportional hazards regression identified 13
independent determinants of HMA. These variables
are listed in table 2 and are divided into two classes:
those that had similar associations with HMA in both
the intensive treatment group and the standard treat-
mentgroup,and thosethat hada different relationship
with HMA in the intensive versus the standard group
(education, low density lipoprotein cholesterol level,
useofanyinsulinatbaseline,andbaselinelevelofhae-
moglobin A1C; P<0.05 for test of interaction).
Baseline covariates associated with an increased risk
for HMA in both the intensive treatment arm and the
standard treatment arm were female gender (P=0.03),
African-American race (compared with non-Hispanic
whites; P<0.0001), history of peripheral neuropathy
(P=0.0300), lower body mass index (P<0.0001), higher
urinealbumintocreatinineratio(P<0.0001),andhigher
levels of serum creatinine (P=0.0010). Each one year
increment in baseline age was associated with a 3%
increaseintheriskforHMA(P<0.0001).Forurinealbu-
min to creatinine ratio, participants with macroalbumi-
nuria (ratio >300) had a higher risk ofHMA thanthose
without abnormal elevation in the ratio of urine albu-
min to creatinine (HR 1.74, 95% CI 1.37 to 2.21),
whereas participants with microalbuminuria (ratio
between 30 and 300 inclusive) were also at increased
risk (HR 1.20, 95% CI 1.02 to 1.44). For serum creati-
nine, participants with renal insufficiency (creatinine
level >114.9 μmol/l (1.3 mg/dl)) were at highest risk of
HMAcomparedwiththose whohadnormalcreatinine
levels(<88.4μmol/l(1.0mg/dl);HR1.66,95%CI1.25
to2.19),andparticipantswithcreatininelevelsbetween
88.4 and114.9 μmol/linclusive werealso athigher risk
(HR 1.21, 95% CI 1.02 to 1.43).
For those predictors with different relationships
according to glycaemia treatment group, lower educa-
tion was associated with an increased risk for HMA in
both groups, but to a greater degree in the standard
treatment group (HR 1.74, 95% CI 1.02 to 2.95) than
intheintensivetreatmentgroup(HR1.38,95%CI1.06
to 1.81). Lower levels of low density lipoprotein cho-
lesterol concentration (<2.59 mmol/l) and higher hae-
moglobinA1Clevelswereassociatedwithanincreased
risk of HMA among participants in the standard treat-
ment group (P<0.0001 for both). Insulin use at rando-
misationwasassociatedwithanincreasedriskofHMA
in both treatment groups (P<0.0001 for both groups,
Overall
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Fig 4 |Risk of hypoglycaemia requiring medical assistance by baseline clinical subgroups. The
dashed vertical line represents the overall intensive treatment to standard treatment hazard
ratio. *Upper 95% confidence interval of 12.67% truncated at 8.00% for haemoglobin A1C
concentration of less than 7.5%
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1.95 in the intensive treatment arm).
Absolute levels of haemoglobin A1C and hypoglycaemia risk
The relationship between glucose control (baseline
haemoglobin A1C concentration; updated average
haemoglobinA1Cconcentration;andmostrecenthae-
moglobin A1C measurement) and HMA in the inten-
sive treatment and the standard treatment groups is
illustrated in fig 6. When the data for these three mea-
suresofglycaemiaweredividedbyquintiles,thecrude
incidence of severe hypoglycaemia was consistently
higher in the intensive group than in the standard
group (fig 6A, 6C, and 6E). Within each treatment
group, however, higher updated average and most
recently measured haemoglobin A1C levels were gen-
erally associated with a higher annual incidence of
HMA, albeit to different degrees.
Figure 6 also illustrates the effect of these three mea-
suresofglycaemiaonthehazardforHMAwithinboth
the standard and the intensive groups after adjustment
forthecovariatesintable 2.Forthestandardtreatment
group, every 1% unit higher baseline haemoglobin
A1C level was associated with a 30% higher risk of
HMA (HR 1.30, 95% CI 1.15 to 1.47; fig 6B). The
risk was 76% higher for every 1% unit higher updated
average haemoglobin A1C concentration (HR 1.76,
95% CI 1.50 to 2.06; fig 6D). For participants in the
intensive treatment group, there was a non-significant
relationshipbetweenbaselinehaemoglobinA1Clevels
and HMA risk (HR 1.01, 95% CI 0.94 to 1.10; fig 6B).
On the other hand, the relationship between updated
average haemoglobin A1C concentration and HMA
was significant, with a 15% higher risk for every 1%
unit higher haemoglobin A1C level (HR 1.15, 95% CI
1.02 to 1.29; fig 6D).
Although the patterns of unadjusted incidence rates
between treatment groups for the most recent haemo-
globin A1C value appear to be very different (fig 6E),
when adjusted for baseline covariates the model pre-
dicted identical, modest relationships between the
most recent haemoglobin A1C measurement and
HMA risk within both glycaemia groups (fig 6F;
P=0.2169 for a test of different lines within intensive v
standard group). Using this model to compare a hae-
moglobin A1C concentration of 9.0% with a reference
value of 7.5% predicts a 12% increase in the risk of
HMA for the higher haemoglobin A1C level (HR
1.12, 95% CI 1.01 to 1.24), whereas comparing a hae-
moglobin A1C concentration of 8.5% with a reference
level of 7.5% predicts a 6% increase in risk (HR 1.06,
95% CI 0.99 to 1.14).
Change in haemoglobin A1C concentration and
hypoglycaemia risk
Similar analyses were done to assess the effect of the
change in haemoglobin A1C after randomisation on
the risk of HMA. Change was expressed in two ways:
a) difference between baseline haemoglobin A1C con-
centration and four month haemoglobin A1C level;
Table 2 |Hazard ratios from model predicting hypoglycaemia requiring medical assistance*
Hazard ratio (95% CI) P value†
Effects for both intensive arm participants and standard arm participants
Female (v male) 1.21 (1.02 to 1.43) 0.0300
Race <0.0001
Non-Hispanic white 1.0
African-American 1.43 (1.20 to 1.71) <0.0001
Hispanic 0.93 (0.68 to 1.27) 0.6500
Other 0.64 (0.47 to 0.88) 0.0100
History of cardiovascular disease (yes v no) 1.10 (0.94 to 1.28) 0.2200
History of peripheral neuropathy (yes v no) 1.19 (1.02 to 1.38) 0.0300
Time since diagnosis of diabetes (years) 0.7394
≤51 . 0
6-10 0.98 (0.77 to 1.24) 0.8500
11-15 1.06 (0.83 to 1.37) 0.6200
16+ 1.37 (1.09 to 1.73) 0.0100
BMI 0.0023
<25 1.0
≥25 to <30 0.78 (0.60 to 1.02) 0.0700
30+ 0.65 (0.50 to 0.85) <0.0001
Albumin to creatinine ratio <0.0001
<30 1.0
30-300 1.20 (1.02 to 1.43) 0.0300
>300 1.74 (1.37 to 2.21) <0.0001
Serum creatinine (μmol/l) 0.0010
<88.4 1.0
88.4-114.9 1.21 (1.02 to 1.43) 0.0300
>114.9 1.66 (1.25 to 2.19) <0.0001
Age (per 1 year increase) 1.03 (1.02 to 1.05) <0.0001
Effects specific to participants in the standard treatment arm
Education
‡ 0.0274
Less than high school 1.74 (1.02 to 2.95) 0.0400
High school graduate 2.31 (1.46 to 3.66) <0.0001
Some college 1.62 (1.01 to 2.62) 0.0500
College graduate or more 1.0
Low density lipoprotein cholesterol level
(≥2.59 mmol/l v <2.59 mmol/l)
‡
0.59 (0.44 to 0.80) <0.0001
On any insulin
‡ 4.08 (2.88 to 5.76) <0.0001
Haemoglobin A1C concentration (1% increase)
‡ 1.30 (1.15 to 1.47) <0.0001
Effects specific to participants in the intensive arm
Education
‡ 0.0422
Less than high school 1.38 (1.06 to 1.81) 0.0200
High school graduate 1.15 (0.90 to 1.47) 0.2600
Some college 1.02 (0.80 to 1.31) 0.8600
College graduate or more 1.0
Low density lipoprotein cholesterol level
(≥2.59 mmol/l v <2.59 mmol/l)
‡
1.04 (0.87 to 1.24) 0.6500
On any insulin
‡ 1.95 (1.62 to 2.35) <0.0001
Haemoglobin A1C concentration (1% increase)
‡ 1.01 (0.94 to 1.10) 0.7500
*Estimates are from a model that included all terms listed in the table. Time since diagnosis of diabetes and
terms representing assignment to either blood pressure or lipid trial, randomisation to the intensive blood
pressure intervention in the blood pressure trial, and randomisation to receive fibrate in the lipid trial were
forced into the model.
†For variables with more than one category, both the overall P value and P values for the specific hazard ratios
relative to the reference category are provided.
‡Education, low density lipoprotein cholesterol level, baseline use of insulin, and baseline haemoglobin A1C
concentration had relationships with hypoglycaemia that were statistically different between intervention
groups. Separate effects are presented within glycaemia groups for these variables. Tests of interactions
between characteristics and glycaemia intervention: P=0.0405 for education; P=0.0010 for any insulin use;
P=0.0090 for baseline haemoglobin A1C concentration; and P=0.0013 for low density lipoprotein cholesterol
category.
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concentration and updated average haemoglobin A1C
level (excluding the baseline). Here, a positive value
represents a drop in haemoglobin A1C concentration.
Individuals randomised to the intensive treatment
group had a higher incidence of HMA for all quintiles
of four month change in haemoglobin A1C concentra-
tion compared with those randomised to standard
treatment,andtheincreaseinriskofHMAamongpar-
ticipants in the intensive glycaemia control arm was
highest in those with the least change in haemoglobin
A1C concentration over four months (fig 7). The find-
ings were similar when change was expressed as the
differencebetweenbaselinehaemoglobinA1Cconcen-
tration and average haemoglobin A1C concentration
(data not shown).
Afteradjustmentforthevariablesinthecomprehen-
sive model described in table 2, the risk of HMA for
every 1% unit decline in haemoglobin A1C concentra-
tion from baseline to four months was 28% (95% CI
19% to 37%) in the standard treatment group and
14% (95% CI 4% to 23%) in the intensive treatment
group (fig 7B). Furthermore, we found that the effect
of the change in haemoglobin A1C concentration was
not independent of baseline haemoglobin A1C level
(P=0.0262 for interaction test). Within the standard
treatment group, a 1% unit decline in haemoglobin
A1C concentration from baseline to four months was
predictive of 37%, 35%, 32%, 30%, 27%, and 24%
lower risks for participants starting at haemoglobin
A1C levels of 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, and
10.0%, respectively. Within the intensive treatment
group, the predicted reductions in the HMA hazard
for a 1% unit decline in haemoglobin A1C concentra-
tion from baseline to four months were 22%, 19%,
16%,13%,10%,and6%forparticipantsstartingathae-
moglobin A1C levels of 7.5%, 8.0%, 8.5%, 9.0%, 9.5%,
and 10.0%, respectively.
Similarresultswerefoundforthedifferencebetween
baselinehaemoglobin A1C concentration and updated
average haemoglobin A1C concentration. Overall, a
1% unit decline from baseline was predictive of a 35%
(95% CI 24% to 44%) and a 15% (95% CI 4% to 24%)
decrease in the risk of HMA within the standard treat-
mentgroupand the intensivetreatmentgroup, respec-
tively. The relationship between the difference in
baselinehaemoglobin A1C concentration and updated
average haemoglobin A1C concentration and the
HMA risk was not dependent on the baseline haemo-
globin A1C value (P=0.2569 for interaction test).
DISCUSSION
Principal findings
As expected, rates of hypoglycaemia were higher
among participants assigned to intensive glycaemia
therapythaninthoseonstandardtherapy.Thegreater
prevalence of HMA compared with events not requir-
ing medical assistance among participants in the
ACCORD study may reflect lack of confidence of
home care givers in their ability to treat severe hypo-
glycaemia in elderly fragile patients. This finding
emphasises the importance of teaching patients with
diabetes how to safely administer oral carbohydrates
such as glucose gels or, when needed, subcutaneous
injections of glucagon.
O u rf i n d i n g so fi n c r e a s e dr i s k sf o rh y p o g l y c a e m i a
among women, African-Americans, the less educated,
the elderly, those with longer duration diabetes, and
those on insulin, regardless of treatment group, will
aid clinicians in identifying patients who may benefit
from special efforts to prevent hypoglycaemia. Multi-
variablemodellingalsoidentifiedahistoryofperipheral
neuropathy and biochemical markers of renal dysfunc-
tion as independent risk factors for severe hypoglycae-
mia.Thesecharacteristicsareconsistentwiththelonger
durationofdiabeteswesawinparticipantswithaHMA.
Given that progressivebetacell dysfunctionisa known
characteristic of type 2 diabetes,
18 those participants
with a longer duration of diabetes probably had more
profound beta cell failure than those who had the dis-
ease for less time. Endogenous insulin response to fluc-
tuations in glucose is essentially absent in people with
advanced beta cell failure. Our finding of an increased
riskofhypoglycaemiainparticipantswithlongduration
ofdiabeteslikelyrepresentsadecreasedabilitytocoun-
ter-regulate glucose changes precipitated by glucose
lowering medications.
Within both the intensiveglycaemia control and the
standard glycaemia control groups, participants who
had a higher baseline haemoglobin A1C concentration
had an increased risk of HMA. After controlling for
other baseline covariates, this effect was only seen in
the standard treatment group. Rapid lowering of
Overall
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Fig 5 |Risk of hypoglycaemia requiring medical assistance by baseline medication subgroups.
The dashed vertical line represents the overall intensive treatment to standard treatment
hazard ratio
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thestudywasnotassociatedwithahigherriskofsevere
hypoglycaemia. On the contrary, participants whose
haemoglobin A1C concentration did not drop quickly
in the first four months had an increased risk of hypo-
glycaemia. These patients were usually on insulin at
baseline and may have subsequently been treated
with higher insulin doses or different combinations of
medications in a potentially unsuccessful attempt to
lower their haemoglobin A1C concentration. Whereas
detailedanalysesofthecontributionofspecificglucose
loweringtherapiestotheriskofseverehypoglycaemia
are beyond the scope of this paper, this unexpected
observation suggests that clinicians should not persist
in trying to intensify glycaemic therapy when a
patient’s haemoglobin A1C level does not fall. Instead,
itmaybewisertoascertainthatthepatientunderstands
and can adhere to their treatment regimens.
Extensive efforts were made to reduce severe hypo-
glycaemia in the ACCORD study, including review
(with feedback) of rates and episodes by both internal
and external experts.
14 Staff were trained to deliver
patient education and provided participants with edu-
cational materials on hypoglycaemia awareness. All
participants were taught to self monitor blood glucose
concentration and were educated on the effect of life-
style changes on risk for hypoglycaemia and how to
recognise and self treat hypoglycaemia, such as keep-
ing glucose tablets (provided by the study) available at
alltimes.Thereductionafterthefirstyearintheannual
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Fig 6 | (A) Incidence (95% CI) of HMA by quintiles of baseline haemoglobin A1C concentration. (B) Hazard ratio for baseline
haemoglobin A1C concentration relative to a haemoglobin A1C concentration of 7.5% (dotted line). (C) Incidence (95% CI) of
hypoglycaemia requiring medical assistance (HMA) by updated average haemoglobin A1C concentration. (D) Hazard ratio for
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Incidence (95% CI) of HMA by most recent haemoglobin A1C measurement. (F) Hazard ratio for most recent haemoglobin A1C
measurement relative to a haemoglobin A1C concentration of 7.5% (dotted line)*. *The model depicted in (F) contains a
significant quadratic term (P=0.04), whereas the models depicted in (B) and (D) were found to be linear on the log scale
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recruited in the vanguard phase and randomised to
the intensivetreatmentgroup suggeststhat experience
with intensive glucose lowering on the part of the par-
ticipant and the care team is important in reducing the
risk of hypoglycaemia.
Comparison with other studies
The rates of severe hypoglycaemia measured in the
ACCORD study were greater than those observed in
the ADVANCE study
5 and less than those seen in
VADT,
7 the two recently reported studies also
designed to determine whether improving glucose
control would reduce cardiovascular events in people
withtype2diabetes.Morethan75%oftheparticipants
in the intensive treatment group of the ACCORD
study were prescribed insulin—a therapy known to
increase hypoglycaemia risk—for some portion of
follow-up, compared with 40% of participants in the
intensive treatment arm of the ADVANCE study.
More than half of the participants in VADT were
already on insulin at baseline, and the haemoglobin
A1C concentration achieved in the intensive treatment
group was higher than that in the ACCORD study
(6.9% v 6.4%, respectively).
It is difficult to compare the rates of hypoglycaemia
intheACCORDstudywiththosereportedincommu-
nity surveys because of the variety of methods used to
define hypoglycaemia, but one survey found that the
estimated proportion of individuals who reported a
biochemical episode of hypoglycaemia (finger stick
glucose concentration <3.33 mmol/l (60 mg/dl)) was
9.4% for those using an oral hypoglycaemia agent and
19.9% among those using insulin.
19 A community
based report from the United Kingdom found that
7% of people on a sulphonylurea and 7-25% of those
on insulin experienced an episode of severe hypogly-
caemia requiring any assistance during a 9-12 month
period.
20 In the ACCORD study, the proportion of
participants in the intensive glycaemia control group
who reported an episode of severe hypoglycaemia
after 3.3 years of follow-up (HA 16.2%; >75% ever
prescribed insulin therapy) was lower than that found
among community patients using insulin.
21
Study strengths and limitations
The collection of detailed information on hypoglycae-
miceventsforalargenumberofindividualscomprises
one of many strengths of this investigation. Standar-
dised procedures were used for documentation of
events within both the intensive and the standard gly-
caemiacontrolgroups.Ourstudydoes,however,have
several limitations.
Firstly, severe hypoglycaemia was self reported by
participants, and validation required participants to
self measure blood glucose levels if hypoglycaemia
was suspected. Participants may not have experienced
hypoglycaemic symptoms severe enough to prompt a
measurement of finger stick glucose, even when blood
glucose levels were less than 2.78 mmol/l (50 mg/dl;
hypoglycaemia unawareness). If so, our estimates of
the incidence of hypoglycaemic events would be too
low. The ACCORD study purposely focused on the
occurrence of severe hypoglycaemia because of the
dangers associated with this condition, and did not
track events that did not meet the prespecified study
definition.TheAmericanDiabetesAssociationrecom-
mends that blood glucose concentrations of less than
3.89 mmol/l (70 mg/dl) be considered indicative of
hypoglycaemia.
22 Using this standard, it is probable
that participants in the ACCORD study experienced
many more episodes of modest hypoglycaemia than
were reported. With our data, we could not determine
whether severe hypoglycaemia was more common in
participants who experienced frequent episodes of
modesthypoglycaemiathaninthosewhoexperienced
little modest hypoglycaemia.
Secondly, all participants were instructed to report
episodes of severe hypoglycaemia within 24 hours of
occurrence. Participants in the intensive treatment
group had more contacts with clinic staff, however, so
they had more opportunities to recall these episodes.
Moreover,itispossiblethatmorefrequentuseoffinger
stickbloodglucosemonitorsintheintensivetreatment
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Fig 7 | (A) Incidence (95% CI) plotted against quintiles of change in haemoglobin A1C concentration between baseline and four
months. (B) Hazard ratio for four month change in haemoglobin A1C concentration relative to a 1% unit decline
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more use of medical assistance.
Thirdly, the ACCORD study did not collect suffi-
cient data to accurately detect episodes of hypoglycae-
mia unawareness, some of which may have been
severe episodes of hypoglycaemia. This shortcoming
would have underestimated the rates of severe hypo-
glycaemia.
Finally, as with all post hoc epidemiologic analyses,
ourresults maybe confoundedby unmeasuredfactors
such as participants’ adherence to their glycaemic
management regimens or the rationale behind investi-
gators’ decisions to alter drugs or doses in the context
of mild hypoglycaemia.
Conclusions
Severe hypoglycaemia was more common in partici-
pants in the ACCORD study randomised to intensive
glycaemia control than in those randomised to stan-
dard glycaemia control. In multivariable analyses,
women, African-Americans, older participants, those
prescribedinsulintherapy,andthosewithlowerlevels
of educational achievement were at increased risk for
severe hypoglycaemia. Participants who were started
on intensive treatment and did not respond promptly
with a fall in haemoglobin A1C concentration were
more vulnerable to severe hypoglycaemia and its pos-
sible consequences.
These observations can provide guidance to clini-
cianswhoattempttointensifypatienttherapyandadjust
glycaemic treatment goals on the basis of individual
risk, as has been recommended in the latest statement
from the American Diabetes Association.
23 Future stu-
dies should be directed at developing strategies to
reduce severe hypoglycaemia in high risk groups.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Intensive glycaemia control in patients with type 2 diabetes increases the risk of an episode
of severe hypoglycaemia
Hypoglycaemia may prevent patients with diabetes from achieving excellent glycaemic
control
WHAT THIS STUDY ADDS
Inthe ACCORD study,patientswith poorglycaemic control(higher baseline haemoglobinA1C
concentration) had a greater risk of hypoglycaemia than those with better glycaemic control,
regardless of treatment group
A greater drop in haemoglobin A1Cconcentration between baseline and four months was not
associated with an increased risk of hypoglycaemia
Individuals started on intensive treatment who do not respond promptly with a fall in
haemoglobin A1Cconcentrationmay bemorelikelytoexperience severehypoglycaemiathan
those who respond promptly to intensification of treatment with a more rapid decline in
haemoglobin A1C level
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